



Ad hoc-Mitteilung gemäss Art. 53 KR

Newron: Zeichnungsvereinbarung über bis zu 2,05 Millionen neu ausgegebene Aktien

Erlös von bis zu EUR 15,0* Mio.

Mailand, Italien, 14. März 2024, 17:45 CET – Newron Pharmaceuticals S.p.A. («**Newron**», oder das «**Unternehmen**») (SIX: NWRN, XETRA: NP5), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Therapien für Patienten mit Erkrankungen des zentralen und peripheren Nervensystems konzentriert, gibt den Abschluss einer Zeichnungsvereinbarung über bis zu 2,05 Millionen neu ausgegebene Aktien mit einem institutionellen Investor bekannt, der sich auf Investitionen in wachstumsstarke Unternehmen diverser Industrien inklusive Biotech und Healthcare spezialisiert hat.

Im Rahmen der Vereinbarung zeichnet der Fonds zunächst 750'000 neu ausgegebene Aktien zu einem Preis von EUR 7,33 pro Aktie, was einem Bruttoerlös von rund EUR 5,5 Mio. entspricht. Darüber hinaus kann der Fonds bis spätestens zum 31. Januar 2025 weitere bis zu 1'300'000 neu ausgegebene Aktien zu einem gemäss einer vereinbarten Formel zu berechnenden Zeichnungspreis erwerben. Die Aktienzeichnungen finden im Rahmen der Kapitalerhöhung statt, über die die Aktionärinnen und Aktionären von Newron im Jahr 2018 abgestimmt haben und die vom Verwaltungsrat des Unternehmens im Jahr 2023 beschlossen und autorisiert wurde.

„Die Investition dieses spezialisierten institutionellen Fonds validiert unsere Strategie der Entwicklung innovativer ZNS-Therapien“, sagte Roberto Galli, CFO von Newron. „Wir erwarten, dass die aufgenommenen Mittel unsere Aktivitäten substantiell über die derzeit anstehenden wichtigen und wertsteigernden Meilensteine in unserer Pipeline hinaus finanzieren werden.“

Die ersten 750'000 neu ausgegebenen Aktien werden nach Zahlung und Abwicklung voraussichtlich am oder um den 20. März 2024 an der SIX Swiss Exchange unter der gleichen ISIN wie die bestehenden Aktien des Unternehmens (ISIN: IT0004147952) zum Handel zugelassen und gehandelt werden. Darüber hinaus werden die neuen Aktien voraussichtlich am Primärmarkt der Düsseldorfer Börse sowie im Quotation Board der Frankfurter Wertpapierbörse (Xetra) zum Handel zugelassen werden.

Über Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) ist ein biopharmazeutisches Unternehmen, das sich auf neuartige Therapien für Erkrankungen des zentralen und peripheren Nervensystems konzentriert. Das Unternehmen hat seinen Hauptsitz im italienischen Bresso in der Nähe von Mailand. Xadago® (Safinamide) ist in der EU, der Schweiz, Großbritannien, den USA, Australien, Kanada, Lateinamerika, Israel, den Vereinigten Arabischen Emiraten, Japan und Südkorea für die Behandlung der Parkinson-Krankheit zugelassen und wird von Newrons Partner Zambon vertrieben. Supernus Pharmaceuticals besitzt die Vermarktungsrechte in den USA. Meiji Seika hält die Entwicklungs- und Vermarktungsrechte in Japan und anderen Schlüsselregionen Asiens. Newron entwickelt zudem Evenamide als mögliche erste Zusatztherapie zur Behandlung von Patienten mit Symptomen der Schizophrenie. Weitere Informationen unter www.newron.com.

* zum aktuellen Wechselkurs CHF-EUR



Für weitere Informationen:

Newron

Stefan Weber – CEO
+39 02 6103 46 26
pr@newron.com

Großbritannien/Europa

Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting
+44 20 3727 1000
SCnewron@fticonsulting.com

Schweiz

Valentin Handschin, IRF
+41 43 244 81 54
handschin@irf-reputation.ch

Deutschland/Europa

Anne Hennecke / Caroline Bergmann, MC Services
+49 211 52925220
newron@mc-services.eu

USA

Paul Sagan, LaVoieHealthScience
+1 617 374 8800, Ext. 112
psagan@lavoiehealthscience.com

Wichtige Hinweise (in englischer Sprache)

This document is not a prospectus within the meaning of the Swiss Financial Services Act and not a prospectus under any other applicable laws. Copies of this document may not be sent to, distributed in or sent from jurisdictions in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, any securities in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the applicable securities laws.

This document is not for publication or distribution in the United States, Canada, Australia or Japan and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States or to publications with a general circulation in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States absent registration under or an exemption from registration under the U.S. Securities Act. There will be no public offering of the securities in the United States.

The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Any offer of securities that may be deemed to be made pursuant to this communication in any member state of the European Economic Area (each an "EEA Member State") that has implemented EU Prospectus Regulation 2017/1129 (together with any amendments thereto and including any applicable implementing measures in any Member State, the "EU Prospectus Regulation") is only addressed to qualified investors in that Member State within the meaning of the EU Prospectus Regulation. There shall be no targeting of the European Economic Area market with regard to a public offering of the securities or an offering other than permitted by Article 1 (3) or (4) of the EU Prospectus Regulation.

This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its



product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed.

Neither Newron nor any of its respective directors, officers, employees, agents, affiliates or advisers is under any obligation to update, complete, revise or keep current the information contained in this document to which it relates or to provide the recipient of with access to any additional information that may arise in connection with it.